December 9, 2024
Supreme Court Declines to Review PhRMA’s Challenge to Arkansas’ 340B Contract Pharmacy Law
340B Program, Arkansas Act 1103, PhRMA, Supreme Court, Contract Pharmacies, Drug Pricing, Federal Preemption
AstraZeneca’s Calquence Combination Shows Promise in Chronic Lymphocytic Leukemia with Fixed-Duration Regimens
AstraZeneca, Calquence, chronic lymphocytic leukemia, CLL, fixed-duration treatment, acalabrutinib, venetoclax, obinutuzumab, AMPLIFY trial
Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017
Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development
Merck’s Investigational ADC Zilovertamab Vedotin Enters Phase 3 with 100% Complete Response Rate in DLBCL Patients
Zilovertamab Vedotin, Antibody-Drug Conjugate (ADC), Diffuse Large B-Cell Lymphoma (DLBCL), Phase 2 Trial, Phase 3 Trial, ROR1, Merck, waveLINE Program
BioAge Labs Halts Phase 2 Obesity Trial Due to Liver Safety Concerns Just Two Months After IPO
BioAge Labs, Phase 2 trial, obesity, liver safety concerns, azelaprag, Eli Lilly, tirzepatide, IPO
Zelicapavir Shows Promising Antiviral Effect in Pediatric RSV Study
Zelicapavir, RSV, Antiviral, Pediatric, Phase 2 Study, Respiratory Syncytial Virus
BIOSECURE Act Excluded from US Defense Bill, Offering Reprieve to Chinese Biotechs
BIOSECURE Act, Chinese biotechs, US defense bill, biotechnology supply chains, national security concerns
Strategic Roadmap for Biologics Manufacturing: Enhancing Efficiency and Flexibility
Biologics manufacturing, Strategic roadmap, Process characterization, Flexibility and efficiency, Regulatory compliance, Biomanufacturing technology roadmap, Precision medicines, Modular facilities, Continuous manufacturing
Diverse Partnerships with Drexel University: Enhancing Educational Opportunities
Drexel University partnerships, educational collaborations, tuition savings, career advancement, professional development
BioAge Labs Discontinues Phase II Obesity Study Due to Safety Concerns, Stock Plummets
BioAge Labs, azelaprag, obesity treatment, Phase II study, safety concerns, liver transaminitis, stock crash